2014•Clinical Lymphoma Myeloma & LeukemiaRequires access

Significant Improvement in Quality of Life (QoL) in Patients With Chronic Myeloproliferative Neoplasms (CMPN) and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib

Pablo Vargas-Viveros, Rafael Hurtado-Monroy, Myrna Candelaria-Hernández

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Myelofibrosis, Ruxolitinib, Constitutional symptoms, Medicine, Quality of life (healthcare), Internal medicine, Adverse effect, Myeloproliferative neoplasm

Back to paper search Browse research topics Original source

Significant Improvement in Quality of Life (QoL) in Patients With Chronic Myeloproliferative Neoplasms (CMPN) and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib — Research Paper | ScholarLens